Eyhance Autorefraction Study
Primary Purpose
Cataract Senile
Status
Unknown status
Phase
Not Applicable
Locations
Austria
Study Type
Interventional
Intervention
Auto and Subjective Refraction
Sponsored by
About this trial
This is an interventional other trial for Cataract Senile
Eligibility Criteria
Inclusion Criteria:
- 21 years old or above
- Operated age-related cataract (pseudophakic patient)
- Tecnis Eyhance ICB00 or Tecnis ZCB00 IOL implanted within 2 to 12 months prior to study related examination
Exclusion Criteria:
- Intra- or Postoperative complication
- patients with severe corneal pathology, severe macular degeneration, severe diabetic retinopathy, etc. that would significantly influence visual outcome
- nystagmus or pathologies that would affect patient fixation
- pregnancy- for women in reproductive age a pregnancy test will be performed.
Sites / Locations
- Hanusch Hospital, Department of OphthalmologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
visual acuity and refractive outcome for Tecnis Eyhance
visual acuity and refractive outcome for Tecnis ZCB00
Arm Description
Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
Outcomes
Primary Outcome Measures
Reproducibility of different refraction methods
Secondary Outcome Measures
Comparability between the devices (autorefractometers)
Full Information
NCT ID
NCT04572334
First Posted
September 30, 2020
Last Updated
October 3, 2020
Sponsor
Vienna Institute for Research in Ocular Surgery
1. Study Identification
Unique Protocol Identification Number
NCT04572334
Brief Title
Eyhance Autorefraction Study
Official Title
Repeatability of Post-operative Refraction in Patients With a Novel CE Marked Monofocal Intraocular Lens
Study Type
Interventional
2. Study Status
Record Verification Date
October 2020
Overall Recruitment Status
Unknown status
Study Start Date
October 2020 (Anticipated)
Primary Completion Date
March 2021 (Anticipated)
Study Completion Date
March 2021 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vienna Institute for Research in Ocular Surgery
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Since 2018, the Tecnis Eyhance ICB00 lens (Johnson&Johnson Vision, AMO Germany GmbH) was introduced, which is a monofocal IOL which has the ability of extended depth of focus improving intermediate vision without the photic phenomena specific for the multifocal IOLs. The Tecnis Eyhance ICB00 is one of our standard IOL, routinely used in our clinic. There is no single outcome measurement that can be thought of as summarizing the efficacy of an IOL, nevertheless visual acuity and refractive outcome are the most important parameters for evaluation. Aim of this study is to determine the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens and compare the outcomes with ZCB00 lens.
Detailed Description
This a prospective observational study that would include pseudophakic patients that have undergone cataract surgery 2 to 12 months prior. A written informed consent will be obtained from each patient. Patients with ICB00 or ZCB00 implanted lenses will be included.
Autorefraction measurements will be performed consecutively, each patient will be measured three times with each device. Two independent observers will perform subjective refraction and will be masked to the autorefraction outcome.
We would like to include 50 eyes with ICB00 and 50 eyes with ZCB00 lens implanted. For the estimation of sample size, we used data from Wang et al. (Wang L, Misra M, Palikaris IG, Koch DD. J Cataract Refract Surg 2002; 28: 276-282) that compared the refractive outcome of pseudophakic eyes and determined a mean spherical equivalent of -0.76 + 0.96 D for group I and -0.44 + 1.13 for group II, thus leading to an effect size of 0.2. The effect size was used for ANOVA test for repeated measurements within factor, with alpha < 0.05, power of 80% and a correlation of 0.5 between the two groups gave us an estimated of sample size of 42 patient. To allow patient drop out a number of 50 eyes will be included per lens group (in total 100 eyes).
When different lenses are implanted (one eye received ZCB00 and the other Eyhance), than both eyes of the patient will be included.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cataract Senile
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
visual acuity and refractive outcome for Tecnis Eyhance
Arm Type
Other
Arm Description
Evaluation the comparability and reproducibility of different refraction methods in patients implanted with Eyhance lens
Arm Title
visual acuity and refractive outcome for Tecnis ZCB00
Arm Type
Other
Arm Description
Evaluation the comparability and reproducibility of different refraction methods in patients implanted with ZCB00 lens
Intervention Type
Other
Intervention Name(s)
Auto and Subjective Refraction
Intervention Description
All patients will be measured with three autorefractometers and two independent observes will perform subjective refraction
Primary Outcome Measure Information:
Title
Reproducibility of different refraction methods
Time Frame
2-12 months
Secondary Outcome Measure Information:
Title
Comparability between the devices (autorefractometers)
Time Frame
2-12 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
21 years old or above
Operated age-related cataract (pseudophakic patient)
Tecnis Eyhance ICB00 or Tecnis ZCB00 IOL implanted within 2 to 12 months prior to study related examination
Exclusion Criteria:
Intra- or Postoperative complication
patients with severe corneal pathology, severe macular degeneration, severe diabetic retinopathy, etc. that would significantly influence visual outcome
nystagmus or pathologies that would affect patient fixation
pregnancy- for women in reproductive age a pregnancy test will be performed.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Oliver Findl, Prof., MD
Phone
+43 1 91021 57564
Email
office@viros.at
First Name & Middle Initial & Last Name or Official Title & Degree
Nino Hirnschall, MD, PhD
Phone
+43 1 91021 57564
Email
nino.hirnschall@googlemail.com
Facility Information:
Facility Name
Hanusch Hospital, Department of Ophthalmology
City
Vienna
ZIP/Postal Code
1140
Country
Austria
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Oliver Findl, Prof. MD
Phone
+43 1 91021 57564
Email
office@viros.at
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Eyhance Autorefraction Study
We'll reach out to this number within 24 hrs